Company intelligence / Profile preview

ProKidney

Winston-Salem, North Carolina, United Statesprokidney.com ↗

Ownership: Public · PROK
Employees: ~330
Development stage: Phase 3

Overview

ProKidney is conducting Phase 3 trials for rilparencel (REACT), which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The company recently decided to discontinue one of its Phase 3 trials (PROACT 2) while focusing on the U.S.-based PROACT 1 trial, which is expected to deliver topline results by Q3 2027. Previous trials indicate that rilparencel is well tolerated by patients with moderate-to-severe CKD.

Therapeutic areas: Nephrology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

rilparencel

Financials

Market cap: $669.1M
Total revenue: $150K
Enterprise value: $491.1M

Beyond the preview

Go deeper on ProKidney.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProKidney.

Explore the full profile